Zynamite (Mangifera indica)

Zynamite is a patented mango leaf extract (Mangifera indica) standardized to a minimum 60% mangiferin, a xanthone C-glucoside that acts as a natural PDE4 inhibitor and monoamine oxidase (MAO) inhibitor to enhance neurotransmitter availability. It is clinically studied for acute cognitive enhancement, mood support, and exercise performance within 60 minutes of a single dose.

Origin & History

Zynamite is a patented extract from mango tree leaves (Mangifera indica), standardized to contain ≥60% mangiferin, a C-glucopyranosyl xanthone polyphenol. Produced by Nektium, it uses extraction methods focusing on mangiferin-rich young leaves and stem bark, with advanced variants like Zynamite® S employing solubilization technologies for enhanced bioavailability.

Historical & Cultural Context

Mangiferin from mango leaves and bark has been used in Ayurvedic and traditional Indian medicine for anti-inflammatory, antidiabetic, and antioxidant purposes. Modern extraction methods leverage this longstanding folk use in regions where mango trees are cultivated, though the branded Zynamite® formulation lacks traditional precedent.

Health Benefits

• Enhanced cognitive performance including attention and memory within 60 minutes of ingestion (moderate evidence from RCT with 119 participants)
• Improved mood states with reduction in tension and confusion at 150mg dose (moderate evidence from same RCT)
• Reduced oxidative stress during athletic performance when combined with luteolin (preliminary evidence from single athlete study)
• Potential metabolic support through AMPK activation and fatty acid oxidation (preliminary evidence from mechanistic studies)
• Blood sugar regulation through alpha-amylase and glucosidase inhibition (in vitro evidence only)

How It Works

Mangiferin, the primary xanthone in Zynamite, inhibits phosphodiesterase-4 (PDE4), which elevates intracellular cyclic AMP (cAMP) levels and downstream PKA signaling, enhancing neuronal activity and cognitive function. It also inhibits monoamine oxidase A and B (MAO-A/MAO-B), slowing degradation of dopamine, serotonin, and norepinephrine, which supports mood and executive function. Additionally, mangiferin modulates Nrf2 antioxidant pathway activation and suppresses pro-inflammatory NF-κB signaling, contributing to reduced oxidative stress during high-intensity exercise.

Scientific Research

A double-blind, placebo-controlled crossover RCT (n=119 university students) demonstrated cognitive and mood benefits of Zynamite® S at 100-150mg doses within 60 minutes. Another RCT combined Zynamite with luteolin in athletes, showing preserved peak power output through RONS attenuation. No meta-analyses or long-term human trials have been conducted to date.

Clinical Summary

A randomized, double-blind, placebo-controlled crossover trial with 119 healthy adults demonstrated that a single 150 mg dose of Zynamite significantly improved attention, executive function, and working memory within 60 minutes of ingestion compared to placebo. The same study found that 150 mg reduced self-reported tension and confusion on the Profile of Mood States (POMS) scale, while a 300 mg dose showed cognitive benefits comparable to 200 mg of caffeine. Separate sports performance research indicated Zynamite combined with quercetin reduced markers of oxidative stress and muscle damage during repeated sprint exercise in trained athletes. Overall evidence is rated moderate, primarily derived from industry-affiliated trials requiring replication by independent research groups.

Nutritional Profile

Zynamite is a patented mango leaf extract (Mangifera indica) standardized to ≥60% mangiferin, a C-glucosyl xanthone polyphenol. Key bioactive compounds include: mangiferin (primary active compound, ≥60% concentration by standardization), norathyriol (active metabolite of mangiferin formed via gut microbiota), isomangiferin, and quercetin glycosides. Secondary polyphenols present include gallic acid, methyl gallate, and benzophenone derivatives. Macronutrient contribution is negligible at typical doses (150–300mg extract). Micronutrient content at supplemental doses is not clinically significant. Bioavailability considerations: mangiferin has inherently limited oral bioavailability (~1–2% in some models) due to poor intestinal absorption as an intact glucoside; however, gut microbiota convert mangiferin to norathyriol, which exhibits superior membrane permeability and CNS penetration. Zynamite's proprietary extraction process is suggested to enhance bioavailability relative to crude mango leaf preparations. Peak plasma concentrations of mangiferin and norathyriol are reported within 1–2 hours post-ingestion, consistent with observed cognitive effects at 60 minutes. Antioxidant capacity is high (ORAC-equivalent), and mangiferin exhibits inhibition of monoamine oxidase (MAO-A and MAO-B), phosphodiesterase (PDE4), and activation of AMPK pathways at relevant concentrations.

Preparation & Dosage

Clinically studied doses include 100-150mg Zynamite® S (standardized to 60% mangiferin, yielding 60-90mg mangiferin) for acute cognitive and mood benefits. Standard Zynamite® uses ≥60% mangiferin standardization, with doses around 140mg extract providing 100mg mangiferin. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Luteolin, Rhodiola rosea, L-theanine, Bacopa monnieri, Alpha-GPC

Safety & Interactions

Zynamite is generally well tolerated in healthy adults at doses of 140–300 mg, with no serious adverse events reported in published clinical trials to date. Because mangiferin inhibits MAO-A and MAO-B, combining Zynamite with prescription MAOIs, serotonergic drugs (SSRIs, SNRIs), or tyramine-rich foods carries a theoretical risk of serotonin syndrome or hypertensive crisis and should be avoided. Individuals taking medications metabolized by CYP3A4 or CYP2C9 should exercise caution, as mangiferin may modulate these hepatic enzymes. Safety data during pregnancy, lactation, and in pediatric populations is absent, so use is not recommended in these groups.